4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...
Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
MedPage Today on MSN
Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy
Continued FDA approval of iptacopan was contingent on 2-year trial data ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare and progressive kidney diseases that often lead to kidney failure. Both involve overactivity in ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Hosted on MSN
6 types of treatment for complement 3 glomerulopathy
Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results